Lineage Cell Therapeutics (LCTX) Profit After Tax (QoQ) (2010 - 2026)
Lineage Cell Therapeutics (LCTX) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -759.64% |
| Dec 31, 2025 | 102.44% |
| Sep 30, 2025 | 2.02% |
| Jun 30, 2025 | -633.61% |
| Mar 31, 2025 | -27.51% |
| Dec 31, 2024 | -8.16% |
| Sep 30, 2024 | 47.90% |
| Jun 30, 2024 | 12.17% |
| Mar 31, 2024 | -37.34% |
| Dec 31, 2023 | 33.29% |
| Sep 30, 2023 | -36.89% |
| Jun 30, 2023 | -18.73% |
| Mar 31, 2023 | 30.69% |
| Dec 31, 2022 | -4.70% |
| Sep 30, 2022 | 10.26% |
| Jun 30, 2022 | 4.57% |
| Mar 31, 2022 | 75.56% |
| Dec 31, 2021 | -270.60% |
| Sep 30, 2021 | -63.39% |
| Jun 30, 2021 | -238.14% |